Clearmind Medicine Inc. (CMND) 10-Year Financial Performance & Capital Metrics

CMND • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutClearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Show more

Revenue $0
EBITDA -$8M +8.4%
Net Income -$5M +56.0%
EPS (Diluted) -1.69 +96.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -235.04% +73.2%
ROIC -
Debt/Equity 0.02
Interest Coverage -221.21

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM63.79%

ROCE

10Y Avg-280.54%

5Y Avg-401.8%

3Y Avg-598.88%

Latest-389.49%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	2.57K	113.38K	56.34K	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-2.57K	-113.38K	-56.34K	-26.7K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-43.08%	0.5%	0.53%
Operating Expenses+	6.67K	254.53K	105.28K	233.22K	3.68M	8.53M	8.74M	8M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	6.67K	254.53K	105.28K	233.22K	3.03M	5.43M	6.6M	4.35M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	0	0	0	646.49K	2.98M	2.14M	1.38M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	113.38K	0	2.27M
Operating Income+	-6.67K	-254.53K	-105.28K	-233.22K	-3.68M	-8.53M	-8.74M	-8M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-37.16%	0.59%	-1.22%	-14.76%	-1.32%	-0.02%	0.08%
EBITDA+	-6.67K	-93.39K	-19.28K	-53.53K	-3.67M	-8.5M	-8.71M	-7.98M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-13%	0.79%	-1.78%	-67.63%	-1.31%	-0.02%	0.08%
D&A (Non-Cash Add-back)	0	161.14K	86K	179.69K	2.57K	30.52K	30.69K	16.78K
EBIT	-26.68K	-217.41K	-86K	-412.91K	-3.69M	-8.52M	-8.74M	-8M
Net Interest Income+	0	0	0	0	0	-19.64K	105.02K	235.06K
Interest Income	0	0	0	0	0	0	57.97K	271.22K
Interest Expense	0	0	0	0	0	19.68K	0	36.16K
Other Income/Expense	0	60K	0	-179.69K	-43.53K	-817.79K	-3.19M	1.21M
Pretax Income+	-6.67K	-194.53K	-105.28K	-412.91K	-3.72M	-9.37M	-11.93M	-4.88M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	40.75K	24.09K	377.97K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.08%
Net Income+	-6.67K	-194.53K	-105.28K	-412.91K	-3.72M	-9.41M	-11.96M	-5.25M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-28.16%	0.46%	-2.92%	-8.01%	-1.53%	-0.27%	0.56%
Net Income (Continuing)	-26.68K	-194.53K	-105.28K	-412.91K	-3.72M	-9.39M	-11.96M	-5.25M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-14.02	-6.42	-9.56	-120.30	-217.20	-42.58	-1.69
EPS Growth %	-	-32.41%	0.54%	-0.49%	-11.58%	-0.81%	0.8%	0.96%
EPS (Basic)	-0.42	-14.02	-6.42	-9.56	-120.30	-168.61	-42.58	-1.69
Diluted Shares Outstanding	122.22K	107.79K	123.33K	181.3K	309.11K	433.34K	2.02M	4.27M
Basic Shares Outstanding	122.22K	107.79K	123.33K	181.3K	309.11K	433.34K	2.02M	4.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Total Current Assets+	110.7K	82.14K	3.79K	332.97K	4.92M	593.31K	5.79M	7.09M
Cash & Short-Term Investments	102.45K	73.69K	688	329.84K	3.71M	440.22K	5.51M	6.86M
Cash Only	102.45K	73.69K	688	329.84K	4.6M	175.77K	5.43M	6.57M
Short-Term Investments	0	0	0	0	0	264.45K	86.11K	289.39K
Accounts Receivable	289	8.45K	3.1K	2.35K	129.8K	37.42K	240.32K	180.88K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	-3.1K	0	0	0	-40.74K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	371	0	3.1K	780	950.06K	101.42K	40.74K	0
Total Non-Current Assets+	18.42K	164.59K	174.59K	179.69K	238.62K	534.66K	158.71K	167.18K
Property, Plant & Equipment	18.42K	164.59K	174.59K	179.69K	20.58K	66.38K	1.25K	51.66K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	-873	0
Intangible Assets	0	0	0	0	198.04K	177.8K	120.18K	108.33K
Long-Term Investments	0	0	0	0	20K	0	0	0
Other Non-Current Assets	0	0	0	0	20K	310.49K	38.15K	7.19K
Total Assets+	129.12K	246.74K	178.38K	512.66K	5.16M	1.13M	5.95M	7.26M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.91%	-0.28%	1.87%	9.06%	-0.78%	4.28%	0.22%
Total Current Liabilities+	65.79K	7.64K	44.57K	13.36K	357.15K	2.64M	4.97M	4.13M
Accounts Payable	832	5.83K	9.68K	3.98K	281.53K	1.03M	617K	526.06K
Days Payables Outstanding	-	-	-	-	39.95K	3.3K	4K	-
Short-Term Debt	0	0	0	0	0	0	0	36.73K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	45.49K	0	0	0	0	1.41M	4.31M	3.48M
Current Ratio	1.68x	10.75x	0.08x	24.92x	13.78x	0.22x	1.17x	1.72x
Quick Ratio	1.68x	10.75x	0.15x	24.92x	13.78x	0.22x	1.17x	1.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.07K	7.64K	12.74K	5.3K	0	0	0	16.42K
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	16.42K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	65.79K	7.64K	44.57K	13.36K	357.15K	2.64M	4.97M	4.15M
Total Debt+	0	0	0	0	0	52.4K	0	53.14K
Net Debt	-102.45K	-73.69K	-688	-329.84K	-4.6M	-123.37K	-5.43M	-6.52M
Debt / Equity	-	-	-	-	-	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-433.61x	-	-221.21x
Total Equity+	63.33K	239.1K	133.81K	499.29K	4.8M	-1.51M	1.36M	3.11M
Equity Growth %	-	2.78%	-0.44%	2.73%	8.62%	-1.31%	1.9%	1.28%
Book Value per Share	0.52	2.22	1.09	2.75	15.53	-3.48	0.67	0.73
Total Shareholders' Equity	63.33K	239.1K	133.81K	499.29K	4.8M	-1.51M	1.36M	3.11M
Common Stock	70K	293K	293K	891.7K	7.91M	9.15M	17.13M	24.17M
Retained Earnings	-6.67K	-201.21K	-306.49K	-539.71K	-4.44M	-13.85M	-18.77M	-24.02M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	147.3K	147.3K	147.3K	1.34M	643.94K	-15.37K	-21.25K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Cash from Operations+	-9.12K	-105.59K	-63.01K	-264.45K	-2.84M	-5.08M	-6.3M	-4.86M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-10.57%	0.4%	-3.2%	-9.72%	-0.79%	-0.24%	0.23%
Net Income	-6.67K	-194.53K	-105.28K	-233.22K	-2.73M	-6.89M	-6.23M	-5.25M
Depreciation & Amortization	0	0	0	180	2.57K	83.07K	41.59K	51.07K
Stock-Based Compensation	0	147.3K	0	0	619.94K	1.65K	366.4K	883.87K
Deferred Taxes	0	0	0	0	0	40.75K	17.37K	103.88K
Other Non-Cash Items	371	-60K	0	-179	-758.24K	-2.15K	210.72K	-512.7K
Working Capital Changes	-2.45K	1.65K	42.28K	-31.23K	25.99K	1.69M	-703.89K	-130.11K
Change in Receivables	-371	-8.08K	5.35K	-28	-157.74K	27.21K	-151.48K	64.95K
Change in Inventory	0	0	-5.35K	28	157.74K	-27.21K	151.48K	0
Change in Payables	0	6.58K	5.1K	-7.44K	343.6K	1.25M	-450.67K	0
Cash from Investing+	-18.42K	-131.17K	-10K	-5.09K	-251.19K	-7.59K	-26.23K	-238.1K
Capital Expenditures	-18.42K	-131.17K	-10K	-10K	-231.19K	-8	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	4.91K	0	-7.58K	-26.23K	33.8K
Cash from Financing+	130K	208K	0	598.7K	7.36M	698.4K	11.66M	6.25M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	130K	-1.52K	0	149.31K	3.01M	115.94K	3.67M	4.1M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.55K	-236.76K	-73.01K	-274.45K	-3.07M	-5.09M	-6.3M	-4.86M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-7.6%	0.69%	-2.76%	-10.17%	-0.66%	-0.24%	0.23%
FCF per Share	-0.23	-2.20	-0.59	-1.51	-9.92	-11.75	-3.11	-1.14
FCF Conversion (FCF/Net Income)	1.37x	0.54x	0.60x	0.64x	0.76x	0.54x	0.53x	0.92x
Interest Paid	0	0	0	0	0	0	4	7
Taxes Paid	0	0	0	0	0	0	12.68K	306.59K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-10.53%	-128.65%	-56.47%	-130.44%	-140.34%	-571.69%	-876.57%	-235.04%
Return on Invested Capital (ROIC)	-	-302.35%	-52.9%	-115.62%	-1482.97%	-	-	-
Debt / Equity	-	-	-	-	-	-	-	0.02x
Interest Coverage	-	-	-	-	-	-433.61x	-	-221.21x
FCF Conversion	1.37x	0.54x	0.60x	0.64x	0.76x	0.54x	0.53x	0.92x

Frequently Asked Questions

Growth & Financials

Clearmind Medicine Inc. (CMND) grew revenue by 0.0% over the past year. Growth has been modest.

Clearmind Medicine Inc. (CMND) reported a net loss of $4.8M for fiscal year 2024.

Dividend & Returns

Clearmind Medicine Inc. (CMND) has a return on equity (ROE) of -235.0%. Negative ROE indicates the company is unprofitable.

Clearmind Medicine Inc. (CMND) had negative free cash flow of $4.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Clearmind Medicine Inc. (CMND) 10-Year Financial Performance & Capital Metrics

CMND • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$8M +8.4%
Net Income -$5M +56.0%
EPS (Diluted) -1.69 +96.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -235.04% +73.2%
ROIC -
Debt/Equity 0.02
Interest Coverage -221.21

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM63.79%

ROCE

10Y Avg-280.54%

5Y Avg-401.8%

3Y Avg-598.88%

Latest-389.49%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	2.57K	113.38K	56.34K	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-2.57K	-113.38K	-56.34K	-26.7K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-43.08%	0.5%	0.53%
Operating Expenses+	6.67K	254.53K	105.28K	233.22K	3.68M	8.53M	8.74M	8M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	6.67K	254.53K	105.28K	233.22K	3.03M	5.43M	6.6M	4.35M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	0	0	0	646.49K	2.98M	2.14M	1.38M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	113.38K	0	2.27M
Operating Income+	-6.67K	-254.53K	-105.28K	-233.22K	-3.68M	-8.53M	-8.74M	-8M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-37.16%	0.59%	-1.22%	-14.76%	-1.32%	-0.02%	0.08%
EBITDA+	-6.67K	-93.39K	-19.28K	-53.53K	-3.67M	-8.5M	-8.71M	-7.98M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-13%	0.79%	-1.78%	-67.63%	-1.31%	-0.02%	0.08%
D&A (Non-Cash Add-back)	0	161.14K	86K	179.69K	2.57K	30.52K	30.69K	16.78K
EBIT	-26.68K	-217.41K	-86K	-412.91K	-3.69M	-8.52M	-8.74M	-8M
Net Interest Income+	0	0	0	0	0	-19.64K	105.02K	235.06K
Interest Income	0	0	0	0	0	0	57.97K	271.22K
Interest Expense	0	0	0	0	0	19.68K	0	36.16K
Other Income/Expense	0	60K	0	-179.69K	-43.53K	-817.79K	-3.19M	1.21M
Pretax Income+	-6.67K	-194.53K	-105.28K	-412.91K	-3.72M	-9.37M	-11.93M	-4.88M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	40.75K	24.09K	377.97K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.08%
Net Income+	-6.67K	-194.53K	-105.28K	-412.91K	-3.72M	-9.41M	-11.96M	-5.25M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-28.16%	0.46%	-2.92%	-8.01%	-1.53%	-0.27%	0.56%
Net Income (Continuing)	-26.68K	-194.53K	-105.28K	-412.91K	-3.72M	-9.39M	-11.96M	-5.25M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.42	-14.02	-6.42	-9.56	-120.30	-217.20	-42.58	-1.69
EPS Growth %	-	-32.41%	0.54%	-0.49%	-11.58%	-0.81%	0.8%	0.96%
EPS (Basic)	-0.42	-14.02	-6.42	-9.56	-120.30	-168.61	-42.58	-1.69
Diluted Shares Outstanding	122.22K	107.79K	123.33K	181.3K	309.11K	433.34K	2.02M	4.27M
Basic Shares Outstanding	122.22K	107.79K	123.33K	181.3K	309.11K	433.34K	2.02M	4.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Total Current Assets+	110.7K	82.14K	3.79K	332.97K	4.92M	593.31K	5.79M	7.09M
Cash & Short-Term Investments	102.45K	73.69K	688	329.84K	3.71M	440.22K	5.51M	6.86M
Cash Only	102.45K	73.69K	688	329.84K	4.6M	175.77K	5.43M	6.57M
Short-Term Investments	0	0	0	0	0	264.45K	86.11K	289.39K
Accounts Receivable	289	8.45K	3.1K	2.35K	129.8K	37.42K	240.32K	180.88K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	-3.1K	0	0	0	-40.74K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	371	0	3.1K	780	950.06K	101.42K	40.74K	0
Total Non-Current Assets+	18.42K	164.59K	174.59K	179.69K	238.62K	534.66K	158.71K	167.18K
Property, Plant & Equipment	18.42K	164.59K	174.59K	179.69K	20.58K	66.38K	1.25K	51.66K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	-873	0
Intangible Assets	0	0	0	0	198.04K	177.8K	120.18K	108.33K
Long-Term Investments	0	0	0	0	20K	0	0	0
Other Non-Current Assets	0	0	0	0	20K	310.49K	38.15K	7.19K
Total Assets+	129.12K	246.74K	178.38K	512.66K	5.16M	1.13M	5.95M	7.26M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.91%	-0.28%	1.87%	9.06%	-0.78%	4.28%	0.22%
Total Current Liabilities+	65.79K	7.64K	44.57K	13.36K	357.15K	2.64M	4.97M	4.13M
Accounts Payable	832	5.83K	9.68K	3.98K	281.53K	1.03M	617K	526.06K
Days Payables Outstanding	-	-	-	-	39.95K	3.3K	4K	-
Short-Term Debt	0	0	0	0	0	0	0	36.73K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	45.49K	0	0	0	0	1.41M	4.31M	3.48M
Current Ratio	1.68x	10.75x	0.08x	24.92x	13.78x	0.22x	1.17x	1.72x
Quick Ratio	1.68x	10.75x	0.15x	24.92x	13.78x	0.22x	1.17x	1.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.07K	7.64K	12.74K	5.3K	0	0	0	16.42K
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	16.42K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	65.79K	7.64K	44.57K	13.36K	357.15K	2.64M	4.97M	4.15M
Total Debt+	0	0	0	0	0	52.4K	0	53.14K
Net Debt	-102.45K	-73.69K	-688	-329.84K	-4.6M	-123.37K	-5.43M	-6.52M
Debt / Equity	-	-	-	-	-	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-433.61x	-	-221.21x
Total Equity+	63.33K	239.1K	133.81K	499.29K	4.8M	-1.51M	1.36M	3.11M
Equity Growth %	-	2.78%	-0.44%	2.73%	8.62%	-1.31%	1.9%	1.28%
Book Value per Share	0.52	2.22	1.09	2.75	15.53	-3.48	0.67	0.73
Total Shareholders' Equity	63.33K	239.1K	133.81K	499.29K	4.8M	-1.51M	1.36M	3.11M
Common Stock	70K	293K	293K	891.7K	7.91M	9.15M	17.13M	24.17M
Retained Earnings	-6.67K	-201.21K	-306.49K	-539.71K	-4.44M	-13.85M	-18.77M	-24.02M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	147.3K	147.3K	147.3K	1.34M	643.94K	-15.37K	-21.25K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024
Cash from Operations+	-9.12K	-105.59K	-63.01K	-264.45K	-2.84M	-5.08M	-6.3M	-4.86M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-10.57%	0.4%	-3.2%	-9.72%	-0.79%	-0.24%	0.23%
Net Income	-6.67K	-194.53K	-105.28K	-233.22K	-2.73M	-6.89M	-6.23M	-5.25M
Depreciation & Amortization	0	0	0	180	2.57K	83.07K	41.59K	51.07K
Stock-Based Compensation	0	147.3K	0	0	619.94K	1.65K	366.4K	883.87K
Deferred Taxes	0	0	0	0	0	40.75K	17.37K	103.88K
Other Non-Cash Items	371	-60K	0	-179	-758.24K	-2.15K	210.72K	-512.7K
Working Capital Changes	-2.45K	1.65K	42.28K	-31.23K	25.99K	1.69M	-703.89K	-130.11K
Change in Receivables	-371	-8.08K	5.35K	-28	-157.74K	27.21K	-151.48K	64.95K
Change in Inventory	0	0	-5.35K	28	157.74K	-27.21K	151.48K	0
Change in Payables	0	6.58K	5.1K	-7.44K	343.6K	1.25M	-450.67K	0
Cash from Investing+	-18.42K	-131.17K	-10K	-5.09K	-251.19K	-7.59K	-26.23K	-238.1K
Capital Expenditures	-18.42K	-131.17K	-10K	-10K	-231.19K	-8	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	4.91K	0	-7.58K	-26.23K	33.8K
Cash from Financing+	130K	208K	0	598.7K	7.36M	698.4K	11.66M	6.25M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	130K	-1.52K	0	149.31K	3.01M	115.94K	3.67M	4.1M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.55K	-236.76K	-73.01K	-274.45K	-3.07M	-5.09M	-6.3M	-4.86M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-7.6%	0.69%	-2.76%	-10.17%	-0.66%	-0.24%	0.23%
FCF per Share	-0.23	-2.20	-0.59	-1.51	-9.92	-11.75	-3.11	-1.14
FCF Conversion (FCF/Net Income)	1.37x	0.54x	0.60x	0.64x	0.76x	0.54x	0.53x	0.92x
Interest Paid	0	0	0	0	0	0	4	7
Taxes Paid	0	0	0	0	0	0	12.68K	306.59K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-10.53%	-128.65%	-56.47%	-130.44%	-140.34%	-571.69%	-876.57%	-235.04%
Return on Invested Capital (ROIC)	-	-302.35%	-52.9%	-115.62%	-1482.97%	-	-	-
Debt / Equity	-	-	-	-	-	-	-	0.02x
Interest Coverage	-	-	-	-	-	-433.61x	-	-221.21x
FCF Conversion	1.37x	0.54x	0.60x	0.64x	0.76x	0.54x	0.53x	0.92x

Frequently Asked Questions

Growth & Financials

Clearmind Medicine Inc. (CMND) grew revenue by 0.0% over the past year. Growth has been modest.

Clearmind Medicine Inc. (CMND) reported a net loss of $4.8M for fiscal year 2024.

Dividend & Returns

Clearmind Medicine Inc. (CMND) has a return on equity (ROE) of -235.0%. Negative ROE indicates the company is unprofitable.

Clearmind Medicine Inc. (CMND) had negative free cash flow of $4.6M in fiscal year 2024, likely due to heavy capital investments.